Chairman of Pharmaceuticals · BridgeBio Pharma, Inc. (BBIO)

Charles Homcy

A named executive officer of BridgeBio Pharma in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,855,805

Salary $500,000Stock awards $0Bonus $100,000

FY2019: $5,975,842

6th of 6 named executive officers at BridgeBio Pharma by FY2020 total.

6 named officers on file for BridgeBio Pharma, FY2020

Charles Homcy’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • BBIO’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how BridgeBio Pharma’s whole pay program stands against its peers

  • BridgeBio Pharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on BBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Charles Homcy’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Charles Homcy compensation by year

BridgeBio Pharma Summary Compensation Table · all 2 fiscal years held
In US dollars, as BridgeBio Pharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$513,808$500,000
Bonus$0$100,000
Stock awards$2,111,579$0
Option awards$3,128,716$1,199,992
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$221,737$55,812
Total$5,975,842$1,855,805

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BridgeBio Pharma, Inc. DEF 14A filed April 30, 2021, accession 0001193125-21-145491, and prior-year filings. Open the filing on EDGAR.

How this page was built: the BridgeBio Pharma, Inc. filed document, accession 0001193125-21-145491. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.

$6.0M
$1.9M
FY19
FY20
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU183,968$13,081,964—
RSU139,339$9,908,396—
RSU20,337$1,446,164—
Option112,422—$29.00
Option181,540—$17.00
Option55,252—$37.45

Per the Outstanding Equity Awards at Fiscal Year-End table in BridgeBio Pharma, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

26 Form 4 lines since the FY2020 proxy (filed April 30, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-22Grant or award—3,990$0.00919,876
2026-06-22Grant or award derivative—5,277$0.005,277
2026-06-20Tax withholding—788$66.27915,886
2025-08-11Sale10b5-150,000$48.00916,674
2025-08-08Sale10b5-158,338$46.64966,674
2025-08-08Sale10b5-1191,662$45.871,025,012
2025-06-27Gift—20,000$0.001,216,674
2025-06-20Grant or award—6,589$0.001,236,674

The 8 most recent of 26 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

BridgeBio Pharma’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Neil KumarChief Executive Officer$10,054,909
Michael HendersonChief Business Officer$7,991,241
Brian StolzChief Operating Officer$5,240,851
Cameron TurtleChief Strategy Officer$4,561,482
Brian StephensonChief Financial Officer$4,163,933
Charles Homcy · this pageChairman of Pharmaceuticals$1,855,805

Board service

BridgeBio Pharma board · FY2021–FY2025
Director compensation in US dollars, as BridgeBio Pharma reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$50,000$274,959$274,988$524,167$1,124,114
FY2024$50,000$0$549,998$517,646$1,117,644
FY2023$50,000$0$549,995$513,200$1,113,195
FY2022$50,000$234,608$549,996$158,000$992,604
FY2021$50,000$109,375$2,199,979$511,600$2,870,954

Each year as the company reported it in BridgeBio Pharma's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: BridgeBio Pharma pays directors a $50,000 cash retainer and $275,000 in Options/RSUs. As stated in BridgeBio Pharma's FY2025 proxy.

The full BridgeBio Pharma compensation record

free company brief

This page is one person within BridgeBio Pharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BridgeBio Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Charles Homcy's compensation dossier · One-time report. No refunds.